Cefrex Injection 2g (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years old should receive 1-2 g (potency) of ceftriaxone once daily via intravenous or intramuscular injection. For infections caused by pathogens exhibiting severe disease or moderate sensitivity, the dosage may be increased to 4 g (potency) once daily. Elderly patients should follow the adult dosage without any modification. In the treatment of gonorrhea, a single intramuscular injection of 250 mg (potency) is recommended. For prevention of infections before and after surgery, it is preferable to administer 1-2 g (potency) once, depending on the risk of infection, 30-90 minutes prior to surgical procedures.

Child administration

Newborns (up to 14 days old) are administered 20-50 mg (potency) per kg of body weight once daily, not exceeding 50 mg (potency) per kg of body weight. Infants and children (15 days to 12 years old) are dosed based on body weight.

This medication should not be mixed or administered simultaneously with solutions or drugs containing calcium. In particular, it should not be given to newborns, as the combination with calcium can cause precipitation and result in serious side effects. Patients who have hypersensitivity reactions to this medication or who are allergic to cephalosporin or penicillin antibiotics should not use it. It should also not be administered to premature infants or newborns with jaundice, hypoalbuminemia, or acidosis. Caution should be exercised when administering to patients with a history of drug allergies or who are predisposed to easily develop allergic symptoms such as bronchial asthma or skin rashes, those with severe kidney impairment, elderly patients, or patients in poor health. In such cases, necessary tests should be conducted frequently and vitamin K should be administered if required. This medication may cause side effects such as headache, dizziness, diarrhea, rash, liver function abnormalities, and decreases in blood cell counts. Rarely, severe allergic reactions, skin abnormalities, decreased kidney function, pancreatitis, and encephalopathy have been reported, necessitating careful attention. During administration, close monitoring should be conducted for any allergic reactions or abnormal symptoms, and if symptoms arise, administration should be stopped immediately, and appropriate treatment should be sought. This medication may interact with other drugs, so caution should be exercised regarding kidney function and bleeding risks, especially when used with diuretics, aminoglycoside antibiotics, or vitamin K antagonists. Women who are pregnant or nursing should only use this medication upon a physician's judgment in cases where safety has not been fully established. It is advisable to avoid administering this medication to newborns and premature infants due to the risk of bilirubin encephalopathy. Elderly patients should be carefully monitored as they may experience more pronounced adverse reactions due to weakened bodily functions, and dosage and intervals should be adjusted accordingly. This medication can affect blood glucose tests or urine test results, which should be taken into account during testing, and intravenous injections should be administered slowly while carefully managing the injection site. The prepared solution should be used as soon as possible and stored at an appropriate temperature.

Serious side effects

Urticaria, severe swelling (edema), shock, difficulty breathing, anaphylaxis and anaphylactoid reactions, severe allergic reactions, severe skin adverse reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory issues (interstitial pneumonia, eosinophilic lung infiltration), liver abnormalities (nuclear jaundice), severe neurological symptoms (encephalopathy, seizures, altered consciousness, myoclonic jerks, status epilepticus), severe edema or

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• elevated liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This medication should be stored in a sealed container to avoid contact with air, preferably at room temperature between 1 and 30 degrees Celsius. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance

A colorless and transparent vial containing a white to pale yellow powder.

Package unit

2g x 10 vials